Format

Send to

Choose Destination
J Diabetes Complications. 2014 May-Jun;28(3):399-405. doi: 10.1016/j.jdiacomp.2014.01.009. Epub 2014 Jan 21.

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.

Author information

1
Tulane University, New Orleans, LA, USA. Electronic address: vfonseca@tulane.edu.
2
Academic Medical Centre, University of Amsterdam, Netherlands.
3
University of California San Diego and VA San Diego Healthcare System, San Diego, CA, USA.
4
Novo Nordisk A/S, Soeborg, Denmark.
5
Novo Nordisk A/S, Aalborg Øst, Denmark.
6
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

AIMS:

To quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions.

METHODS:

A patient-level pooled analysis of six phase 3, randomized trials was conducted.

RESULTS:

The analysis included 2792 randomized patients. In the intention-to-treat population (n=2783), mean [±SE] SBP reductions from baseline with liraglutide 1.2 mg (2.7 [0.8] mmHg) and 1.8 mg (2.9 [0.7] mmHg) once daily were significantly greater than with placebo (0.5 [0.9] mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8 mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson's correlation coefficient: 0.08-0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8 mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1 bpm increase with placebo (P<0.0001 for each dose versus placebo).

CONCLUSIONS:

Liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00294723 NCT00318422 NCT00318461 NCT00331851 NCT00333151 NCT00518882.

KEYWORDS:

Blood pressure; Hypertension; Liraglutide; Type 2 diabetes

PMID:
24561125
PMCID:
PMC4231710
DOI:
10.1016/j.jdiacomp.2014.01.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center